Identification of Metastasis-Associated Receptor Tyrosine Kinases in Non–Small Cell Lung Cancer
Open Access
- 1 March 2005
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (5), 1778-1782
- https://doi.org/10.1158/0008-5472.can-04-3388
Abstract
Development of distant metastasis after tumor resection is the leading cause of death in early-stage non–small cell lung cancer (NSCLC). Receptor tyrosine kinases (RTK) are involved in tumorigenesis but only few RTKs have been systematically studied in NSCLC. Here, we provide quantitative real-time reverse transcription-PCR expression data of all RTKs (n = 56) in primary tumors of 70 patients with early-stage (I-IIIA) NSCLC. Overall, 33 RTKs were expressed in at least 25% of the patients. Several RTKs were significantly expressed higher in tumors that ultimately metastasized. The hazard risk for metastasis development in stage I/II disease was increased at least 3-fold for tumors with high expression levels of insulin receptor, neurotrophic tyrosine receptor kinase 1, epidermal growth factor receptor, ERBB2, ERBB3, platelet-derived growth factor receptor β, fibroblast growth factor receptor 1, or leukocyte tyrosine kinase. Relative risks were reduced 3-fold by expression of EPHB6 or DKFZ1. Three members of the epidermal growth factor receptor family were associated with a high risk of metastasis, emphasizing the validity of our data. High ERBB3 expression was significantly associated with decreased survival. Taken together, our genome-wide RTK expression map uncovered the previously unknown value of several RTKs as potential markers for prognosis and metastasis prediction in early-stage NSCLC. The identified RTKs represent promising novel candidates for further functional analyses.Keywords
This publication has 22 references indexed in Scilit:
- Genome-wide screening for prognosis-predicting genes in early-stage non-small-cell lung cancerLung Cancer, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancerOncogene, 2003
- Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLCJournal of Clinical Oncology, 2003
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002
- Role of the Insulin-Like Growth Factor Family in Cancer Development and ProgressionJNCI Journal of the National Cancer Institute, 2000
- A novel method for real time quantitative RT-PCR.Genome Research, 1996
- Real time quantitative PCR.Genome Research, 1996
- Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtypeEuropean Journal Of Cancer, 1995